Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thermo Fisher ScientificBSP:TMOS34 -0.56%74 Debt-to-Equity is 0.83 as of Mar. 2026, which is 15% above its 10-year median of 0.72. GuruFocus rates BSP:TMOS34 with a GF Score™ of 74/100 and a GF Value™ of R$62.63 (Fairly Valued). The stock has 5 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Thermo Fisher Scientific ranks worse than 78.14% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Thermo Fisher Scientific's Debt-to-Equity or its related term are showing as below:
BSP:TMOS34'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.51 Med: 0.72 Max: 0.89
Current: 0.83
During the past 13 years, the highest Debt-to-Equity Ratio of Thermo Fisher Scientific was 0.89. The lowest was 0.51. And the median was 0.72.
BSP:TMOS34's Debt-to-Equity is ranked worse than 78.14% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.33
vs BSP:TMOS34: 0.83
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thermo Fisher Scientific Debt-to-Equity Related Terms
Thermo Fisher Scientific Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:TMOS34 vs DHR, IDXX, A: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Thermo Fisher Scientific's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thermo Fisher Scientific Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Thermo Fisher Scientific's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thermo Fisher Scientific (BSP:TMOS34) has a Debt-to-Equity of 0.83 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Thermo Fisher Scientific and its competitors. This is 15% above median its historical median of 0.72. Over the past decade, Thermo Fisher Scientific's Debt-to-Equity has ranged from 0.51 to 0.89. According to the industry distribution chart, Thermo Fisher Scientific ranks #143 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 78.1%.
Is Thermo Fisher Scientific's Debt-to-Equity too high?
Thermo Fisher Scientific's current Debt-to-Equity of 0.83 is 15% above median its 10-year median of 0.72. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 0.89. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Thermo Fisher Scientific's value of 0.83 is 151.5% above this industry median. Based on the distribution chart, Thermo Fisher Scientific ranks #143 out of 183 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Thermo Fisher Scientific has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's Debt-to-Equity compare to DHR and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Thermo Fisher Scientific ranks #143 out of 183 companies for Debt-to-Equity. This places Thermo Fisher Scientific in the lower half of its industry. The industry median Debt-to-Equity is 0.33. Thermo Fisher Scientific's value of 0.83 is 151.5% above this benchmark. Historically, Thermo Fisher Scientific's own Debt-to-Equity has ranged from 0.51 to 0.89 over the past decade. While the company's 10-year median is 0.72 vs. the industry median of 0.33, Thermo Fisher Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thermo Fisher Scientific's current Debt-to-Equity of 0.83 is 151.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Thermo Fisher Scientific and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thermo Fisher Scientific's current Debt-to-Equity is 0.83, which is 15% above median its own 10-year median of 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Fairly Valued. The stock's GF Value™ is R$62.63, compared to a current price of R$56.89 — trading 9.2% below its estimated fair value. The current Debt-to-Equity is 0.83, which is 15% above median its 10-year median of 0.72 and 151.5% above the Medical Diagnostics & Research industry median of 0.33. Thermo Fisher Scientific's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current Debt-to-Equity is 0.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?
Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued.
The current stock price of R$56.89 is trading 9.2% below its estimated GF Value™ of R$62.63.
GuruFocus considers Thermo Fisher Scientific to be Fairly Valued.
Key valuation signals for BSP:TMOS34:
Debt-to-Equity: 0.83 (15% above median its 10-year median of 0.72)
GF Value™: R$62.63 vs. price of R$56.89 (9.2% below fair value)
Industry Position: 151.5% above the Medical Diagnostics & Research median (#143 of 183)
No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
74GF Score
Get the complete analysis for BSP:TMOS34
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:TMOS34 has been successfully added to your 
